Drug intelligence / Profile preview

scAAV9-GFP

Development stage: Unknown
Lead developer: Abeona Therapeutics
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intrathecal

Overview

scAAV9-GFP is a self-complementary adeno-associated virus serotype 9 (scAAV9) vector engineered to deliver the gene encoding Green Fluorescent Protein (GFP). It is primarily utilized in research as a reporter or control vector in gene therapy studies to track gene delivery, transduction efficiency, and cellular localization without exerting a therapeutic effect. The self-complementary nature of the vector allows for rapid expression of the transgene.

Targets

AAVR (AAV receptor)

Beyond the preview

Go deeper on scAAV9-GFP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on scAAV9-GFP.

Explore the full profile